dendreon synergy

Some nice trading sentiment for Dendreon over the last two weeks with an approximate 20% rise in the share price on the NASDAQ.

Deutsche Bank are projecting a 50% upside for Dendreon but the chatter is that it will go alot higher. The assumption is that Provenge will become a blockbuster product in the fight against metastatic Prostate cancer.

The expectation is that the approval process will be filed in late 2009 with a subsequent approval in early 2010. Interestingly enough, Deutsche Bank notes that investors are likely placing too little value on the FDA approval chances. It also noted that an additional approval in the European Union is not reflected in the shares.

Could the same be said about Prima? My guess is yes!